{"disease":{"id":"neurotoxicity-syndromes","name":"neurotoxicity syndromes"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03954106","title":"A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT04150913","title":"A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}